对于患有同卵性家族高胆固醇血症的儿科患者,埃维纳库马布
Albert Wiegman1, Susanne Greber-Platzer2, Shazia Ali3
1Department of Paediatrics, Amsterdam University Medical Centers, Location University of Amsterdam, The Netherlands (A.W., M.D.R.).
在患有同胞性家族性高胆固醇血症 (HoFH) 的儿科患者中,埃维纳库马布显著降低了近一半的LDL- C. 这种新疗法为患有难以治疗的脂质疾病的高风险儿童提供了一个重要的新选择.
科学领域:
- 心血管遗传学
- 药理学
- 儿童脂质学
背景情况:
- 同胞性家族高胆固醇血症 (HoFH) 是一种罕见的遗传性疾病,由于LDL受体缺陷,导致LDL-C严重升高.
- 高水平的LDL-C在子宫内开始,导致早期动脉样硬化,儿童缺乏有效的治疗方法.
- 现有的治疗方法往往无法在年轻的HoFH患者中充分控制LDL-C,因此需要新的方法.
研究的目的:
- 评估新型的LDL受体独立降脂疗法evinacumab的疗效和安全性.
- 评估埃维纳库马布对LDL-C和其他脂质参数的影响.
- 确定埃维纳库马布在这个年轻,高风险人群中的安全性.
主要方法:
- 一项第三阶段的开放性研究 (B部分) 招募了14名儿童患者 (5至11岁) 具有经遗传证明的HoFH和LDL- C>130 mg/ dL.
- 患者每4周内服用15毫克/ 千克的静脉治疗,此外还提供优化降脂疗法.
- 治疗持续时间为24周,在整个研究中对疗效和安全性进行了评估.
主要成果:
- 埃维纳库马布表现出快速而持久的LDL- C降低,从基线到第24周的平均降低为-48. 3%.
- 在ApoB (-41. 3%),非HDL- C (-48. 9%) 和总胆固醇 (-49. 1%) 中也观察到显著的降低.
- 大多数不良事件是轻微的,不被认为与治疗相关;14名患者中只有2名出现与治疗相关的不良事件 (恶心,腹痛).
结论:
- 埃维纳库马布是一种新且有效的治疗方法,用于治疗不充分控制LDL- C的儿童HFH患者.
- 在这种极度高风险且难以治疗的群体中,该疗法可显著降低近一半的LDL-C水平.
- 埃维纳库马布为治疗严重高胆固醇血症的儿童提供了一种有价值的新疗法.
更多相关视频
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Myocarditis III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiepileptic Drugs: Glutamate Antagonists
